Logo image of BDRX

BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Fundamental Analysis

NASDAQ:BDRX - Nasdaq - US59564R8079 - ADR - Currency: USD

1.14  -0.01 (-0.87%)

After market: 1.2 +0.06 (+5.26%)

Fundamental Rating

1

Taking everything into account, BDRX scores 1 out of 10 in our fundamental rating. BDRX was compared to 559 industry peers in the Biotechnology industry. BDRX may be in some trouble as it scores bad on both profitability and health. BDRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BDRX had negative earnings in the past year.
In the past year BDRX has reported a negative cash flow from operations.
BDRX had negative earnings in each of the past 5 years.
In the past 5 years BDRX always reported negative operating cash flow.
BDRX Yearly Net Income VS EBIT VS OCF VS FCFBDRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

BDRX has a Return On Assets (-38.76%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -68.84%, BDRX is in line with its industry, outperforming 56.17% of the companies in the same industry.
Industry RankSector Rank
ROA -38.76%
ROE -68.84%
ROIC N/A
ROA(3y)-81.49%
ROA(5y)-102.56%
ROE(3y)-154.1%
ROE(5y)-168.96%
ROIC(3y)N/A
ROIC(5y)N/A
BDRX Yearly ROA, ROE, ROICBDRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BDRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDRX Yearly Profit, Operating, Gross MarginsBDRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

BDRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BDRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BDRX has been increased compared to 5 years ago.
The debt/assets ratio for BDRX is higher compared to a year ago.
BDRX Yearly Shares OutstandingBDRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
BDRX Yearly Total Debt VS Total AssetsBDRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -10.66, we must say that BDRX is in the distress zone and has some risk of bankruptcy.
BDRX's Altman-Z score of -10.66 is on the low side compared to the rest of the industry. BDRX is outperformed by 75.13% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that BDRX is not too dependend on debt financing.
BDRX has a Debt to Equity ratio of 0.07. This is in the lower half of the industry: BDRX underperforms 63.51% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -10.66
ROIC/WACCN/A
WACC8.2%
BDRX Yearly LT Debt VS Equity VS FCFBDRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

BDRX has a Current Ratio of 1.75. This is a normal value and indicates that BDRX is financially healthy and should not expect problems in meeting its short term obligations.
BDRX's Current ratio of 1.75 is on the low side compared to the rest of the industry. BDRX is outperformed by 79.07% of its industry peers.
BDRX has a Quick Ratio of 1.75. This is a normal value and indicates that BDRX is financially healthy and should not expect problems in meeting its short term obligations.
BDRX has a worse Quick ratio (1.75) than 78.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.75
Quick Ratio 1.75
BDRX Yearly Current Assets VS Current LiabilitesBDRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 97.03% over the past year.
BDRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)97.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.4%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

BDRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.21% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.34%
EPS Next 2Y11.8%
EPS Next 3Y12.21%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDRX Yearly Revenue VS EstimatesBDRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2027 2M 4M 6M 8M
BDRX Yearly EPS VS EstimatesBDRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2023 2024 2025 2026 2027 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BDRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BDRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDRX Price Earnings VS Forward Price EarningsBDRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDRX Per share dataBDRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as BDRX's earnings are expected to grow with 12.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.8%
EPS Next 3Y12.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BDRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODEXA PHARMACEUTICALS-ADR

NASDAQ:BDRX (6/10/2025, 8:00:01 PM)

After market: 1.2 +0.06 (+5.26%)

1.14

-0.01 (-0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-12 2023-09-12
Earnings (Next)N/A N/A
Inst Owners29.86%
Inst Owner Change200.61%
Ins Owners3.64%
Ins Owner ChangeN/A
Market Cap3.30M
Analysts85.71
Price Target18.36 (1510.53%)
Short Float %8.56%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-91%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-4.33
EYN/A
EPS(NY)-3.53
Fwd EYN/A
FCF(TTM)-6.09
FCFYN/A
OCF(TTM)-5.73
OCFYN/A
SpS0
BVpS3.89
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.76%
ROE -68.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-81.49%
ROA(5y)-102.56%
ROE(3y)-154.1%
ROE(5y)-168.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 304.72%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.75
Quick Ratio 1.75
Altman-Z -10.66
F-Score3
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)138.58%
Cap/Depr(5y)102.46%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.4%
EPS Next Y33.34%
EPS Next 2Y11.8%
EPS Next 3Y12.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-83.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.62%
OCF growth 3YN/A
OCF growth 5YN/A